查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011320

缓释注射剂市场：按产品类型、聚合物类型、给药途径、应用和最终用户划分 - 全球市场预测（2026-2032 年）

Sustained Release Injectables Market by Product Type, Polymer Type, Route Of Administration, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，缓释注射药物市场价值将达到 24.5 亿美元，到 2026 年将成长至 26 亿美元，到 2032 年将达到 40.1 亿美元，复合年增长率为 7.24%。

主要市场统计数据
基准年（2025 年） 24.5亿美元
预计年份（2026年） 26亿美元
预测年份（2032年） 40.1亿美元
复合年增长率（） 7.24%

对不断发展的缓释注射药物市场进行权威概述，重点在于影响策略决策的技术、监管和商业性因素。

缓释注射剂已成为先进治疗递送系统的核心支柱，重塑了慢性病、癌症治疗方法和特殊疗法的给药方式。本执行摘要整合了目前主导缓释平台的技术、监管和商业性趋势，重点关注其对製造商、临床开发人员、合约服务供应商和医疗保健服务体系的下游影响。此外，本概要也着重阐述了产业领导者为维持临床意义和商业性可行性而必须应对的关键转折点。

聚合物科学的进步、设备整合、监管期望和支付方审查的融合如何重新定义产品开发和商业化策略。

缓释注射药物领域正经历着一场变革，这主要得益于聚合物科学和器械工程的进步，以及对以患者为中心的治疗方法的重新关注。聚合物技术的创新正在加速药物释放动力学和生物降解特性的调控，从而更精准地结合药理学和临床需求。同时，器械的小型化和复合产品的整合正在拓展给药途径，这些途径能够在维持持续治疗浓度的同时，减轻患者的负担。

本检验了美国关税政策的变化如何重塑整个注射药物价值链的筹资策略、製造经济和供应链韧性。

美国关税措施的实施对缓释注射剂产业生态系统产生了重大影响，波及组件采购、生产经济效益和策略供应链设计。关税推高了进口原材料和成品组件的成本，影响采购决策，促使製造商重新评估供应商合约、库存政策以及製造地的地理分布。在此背景下，为了降低贸易政策波动带来的风险，企业正在加速重新评估近岸外包和多元化策略。

了解产品类型、聚合物化学、给药途径、治疗应用和最终用户管道之间的相互联繫，以及它们如何决定开发重点和市场定位。

对细分市场的详细分析揭示了产品类型选择、聚合物选择、给药途径、治疗应用和终端用户管道如何共同决定开发路径和商业性可行性。诸如药筒、植入式帮浦、预填充式注射器和未填充管瓶等产品类型，各自在设备整合和填充方面都面临不同的挑战。这些选择受到预期释放曲线、患者群体和给药环境的影响。聚合物类型大致可分为两大类：可生物分解聚合物和不可生物降解聚合物。可生物降解聚合物，例如聚己内酯、聚乳酸和聚乳酸-羟基乙酸共聚物，具有可预测的吸收曲线，适用于单次给药的持续释放。不可生物降解聚合物，例如聚乙烯和聚硅氧烷，则为需要回收和长期耐久性的应用提供了不同的机械稳定性和长期释放平台。

全球医疗保健市场在监管、临床环境和生产环境方面的区域差异正在重塑打入市场策略和投资重点。

区域趋势对缓释注射剂的研发重点、报销框架和分销路径有显着影响，因此，针对不同区域采取差异化策略至关重要。在美洲，监管管道和支付体系创造了一个环境，​​即临床证据和卫生经济学是市场准入的核心，製造商通常优先考虑以病人为中心的医疗设备和符合价值医疗理念的疗效研究。此外，美洲拥有强大的合约研发生产（CDMO）能力，使其成为规模化生产和商业化活动的中心。

策略伙伴关係、基于平台的经营模式以及差异化的製造能力，正在定义我们在缓释注射药物领域的竞争优势。

为了应对缓释注射剂的技术复杂性，製造商、供应商和服务供应商之间的竞争格局正在朝着更深入的合作和专业化方向发展。成熟的製药公司越来越多地与材料科学专家和器械开发公司合作，以加速复杂产品的开发；而合约开发和生产组织（CDMO）则透过整合製剂专业知识、无菌填充和器械组装等服务来脱颖而出。这种互动提升了与聚合物製剂和器械介面相关的智慧财产权的重要性，使得战略许可和交叉许可成为获取基础技术的常用手段。

为降低缓释注射剂的研发风险、加强供应链、加速市场推广提供实际有效的建议。

产业领导者应优先采取一系列切实可行且影响深远的措施，将技术进步转化为永续的商业性成果。首先，应实现聚合物和组件来源多元化，以降低贸易中断风险，确保持续供应。积极评估替代供应商，并在条件允许的情况下实施双重采购策略。其次，应在研发早期阶段投资于材料表征和设备相容性测试，以降低后期整合挑战的风险，并加快监管申报流程。第三，应设计以患者为中心的临床项目，并纳入真实世界数据（REW）收集，以满足支付方对提高用药依从性和改善治疗效果的要求。

我们采用多方面的研究途径，结合监管审查、专家访谈、专利和文献分析以及供应商分析，确保了检验策略建议的有效性。

本执行摘要所依据的分析融合了多种研究途径，以确保其稳健性和可操作性。该调查方法包括对关键监管文件和临床试验註册资讯的全面审查，对包括製剂科学家、器械工程师、法规事务专家和销售主管在内的各领域专家的有针对性访谈，以及对专利申请和科学文献的系统性评估，以了解创新轨迹。供应链映射和供应商能力评估是利用检验的贸易和采购资料集进行的，并辅以专家检验。

结论强调了整合科学、营运和商业性策略以实现长效注射药物治疗方法潜力的迫切性。

缓释注射药物是材料科学、医疗设备工程和临床策略交叉融合的策略领域，它正在重塑多种疾病领域的治疗方式。该行业正处于转折点，成功的商业化不仅需要卓越的药理特性，还需要整合解决方案，以应对生产製造的复杂性、监管要求、对支付方的价值提案以及患者接受途径。能够整合跨学科能力、确保稳健的供应链并产生可靠的真实世界数据的机构将获得明显的竞争优势。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章：缓释注射剂市场：依产品类型划分

  • 墨水匣
  • 嵌入式泵浦
  • 预填充式注射器
  • 未填充的管瓶

第九章：缓释注射剂市场：依聚合物类型划分

  • 可生物降解聚合物
    • PCL
    • PLA
    • PLGA
  • 不可生物降解聚合物
    • 聚乙烯
    • 聚硅氧烷

第十章：缓释注射剂市场：依给药途径划分

  • 硬脊膜外麻醉
  • 肌肉内部
  • 玻璃体腔内
  • 皮下

第十一章：缓释注射剂市场：依应用领域划分

  • 荷尔蒙疗法
  • 肿瘤学
    • 骨髓恶性肿瘤
    • 固体癌
      • 乳癌
      • 肺癌
  • 疼痛管理
  • 疫苗

第十二章：缓释注射剂市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 家庭医疗保健
  • 医院

第十三章：缓释注射剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：缓释注射剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：缓释注射剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国缓释注射剂市场

第十七章：中国缓释注射剂市场

第十八章 竞争格局

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • Alkermes plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • DSM-Firmenich Group
  • DURECT Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Halozyme Therapeutics, Inc.
  • Hoffmann-La Roche Ltd
  • Indivior PLC
  • Johnson & Johnson
  • MedinCell SA
  • Novartis AG
  • Oakwood Laboratories, LLC
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Pharmathen SA
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • ViiV Healthcare Limited
Product Code: MRR-43078BB92C8D

The Sustained Release Injectables Market was valued at USD 2.45 billion in 2025 and is projected to grow to USD 2.60 billion in 2026, with a CAGR of 7.24%, reaching USD 4.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.45 billion
Estimated Year [2026] USD 2.60 billion
Forecast Year [2032] USD 4.01 billion
CAGR (%) 7.24%

A definitive introduction to the evolving sustained release injectables landscape framing technological, regulatory, and commercial drivers shaping strategic decision-making

Sustained release injectables have become a central pillar of advanced therapeutic delivery, reshaping how chronic conditions, oncology regimens, and specialty therapies are administered. This executive summary synthesizes the current technological, regulatory, and commercial dynamics governing sustained release platforms, with an eye to the downstream implications for manufacturers, clinical developers, contract service providers, and healthcare delivery systems. It frames the critical inflection points that industry leaders must navigate now to maintain clinical relevance and commercial viability.

The analysis emphasizes material science innovation, device integration, clinical adoption pathways, and the operational realities of complex supply chains. It highlights the convergence of polymer chemistry, minimally invasive delivery mechanisms, and patient-centered design, which together dictate the performance, safety, and acceptance of long-acting formulations. Throughout the report, attention is paid to how regulatory expectations and payer considerations increasingly demand robust real-world evidence and demonstrable improvements in adherence and outcomes.

Readers will find a concise synthesis of strategic considerations, followed by targeted recommendations to optimize portfolio decisions, manufacturing capacity, and market access approaches. The intention is to equip decision-makers with a practical, evidence-driven perspective that supports informed investment and partnership choices in a competitive, fast-evolving landscape.

How converging advances in polymer science, device integration, regulatory expectations, and payer scrutiny are redefining product development and commercialization strategies

The sustained release injectables landscape is undergoing transformative shifts driven by advances in polymer science, device engineering, and a renewed focus on patient-centric therapeutic regimens. Polymer innovation has accelerated the ability to tune release kinetics and biodegradation profiles, enabling more precise alignment between pharmacology and clinical need. Concurrently, device miniaturization and combination product integration have expanded the range of administration routes that can deliver sustained therapeutic levels with reduced patient burden.

Regulatory frameworks are also evolving, with authorities placing greater emphasis on robust characterization of drug-device interfaces, long-term safety monitoring, and post-market performance data. This has raised the bar for early development programs, making cross-functional evidence generation-combining pharmacokinetics, biocompatibility, and human factors-an operational necessity. In parallel, healthcare payers are scrutinizing value propositions more closely, pushing sponsors to demonstrate adherence benefits and downstream cost offsets rather than relying solely on pharmacologic differentiation.

On the commercial front, strategic collaboration between originators, specialty manufacturers, and contract development and manufacturing organizations is shaping new delivery pathways. Supply chain resilience and sourcing of critical polymers have become board-level concerns, prompting investments in qualified suppliers and regional manufacturing footprints. Taken together, these shifts require integrated strategies that balance scientific rigor, regulatory foresight, and pragmatic commercialization planning to translate technological promise into durable patient and market outcomes.

Examining how evolving United States tariff measures are reshaping sourcing strategies, manufacturing economics, and supply chain resilience across the injectable value chain

The introduction of tariff measures in the United States has material implications for the sustained release injectables ecosystem, affecting component sourcing, manufacturing economics, and strategic supply chain design. Tariffs that increase the cost of imported raw materials and finished components influence procurement decisions, prompting manufacturers to reassess supplier contracts, inventory policies, and the geographic distribution of manufacturing sites. This environment has accelerated reconsideration of nearshoring and diversification strategies to reduce exposure to trade policy volatility.

Operationally, increased input costs can compress margins for developers and contract manufacturers alike, creating pressure to optimize manufacturing yields, reduce scrap, and invest in process intensification. Firms are responding by negotiating longer-term supplier agreements with greater price stability, qualifying alternate polymer suppliers, and exploring substitution pathways where performance and regulatory allowances permit. At the same time, trade policy-induced cost shifts are encouraging a re-evaluation of total landed cost models that factor in duties, logistics complexity, and time-to-market implications rather than unit price alone.

From a strategic vantage point, tariffs have heightened the importance of regulatory and customs expertise within commercial planning. Companies now factor tariff scenarios into go/no-go decisions for facility investments and licensing agreements. In addition, partnerships and vertical integration strategies have surfaced as viable mitigants, enabling better control over critical inputs and reducing vulnerability to sudden policy changes. Ultimately, the cumulative impact of trade measures underscores the need for agile sourcing, strengthened supplier relationships, and disciplined cost engineering to preserve competitiveness in a tighter global trade environment.

Understanding how intertwined product types, polymer chemistries, administration routes, therapeutic applications, and end-user channels determine development priorities and market positioning

A nuanced view of segmentation reveals how product type choice, polymer selection, route of administration, therapeutic application, and end-user channel jointly determine development pathways and commercial viability. Product types such as cartridges, implantable pumps, pre-filled syringes, and unfilled vials each impose distinct device integration and filling challenges; their selection is influenced by intended release profile, patient population, and administration setting. Polymer type choices divide broadly into biodegradable and non-biodegradable families, with biodegradable classes such as polycaprolactone, polylactic acid, and poly(lactic-co-glycolic acid) offering predictable resorption profiles suitable for single-administration sustained release, while non-biodegradable options like polyethylene and polysiloxanes provide alternative mechanical stability and long-term release platforms where retrieval or extended durability is necessary.

Route of administration is a decisive axis: epidural, intramuscular, intravitreal, and subcutaneous deliveries present unique formulation and device constraints tied to tissue environment, diffusion characteristics, and procedural requirements. Application area shapes clinical development imperatives; hormonal therapies and vaccines generally prioritize safety and adherence enhancement, pain management demands fine-tuned kinetics to balance efficacy and tolerability, and oncology applications, segmented into hematological malignancies and solid tumors, carry heightened expectations for targeted delivery and integration with systemic regimens. Within solid tumors, breast cancer and lung cancer subtypes drive specific dosing schedules and co-therapy compatibility considerations.

End-user context influences final product design and commercialization strategy. Ambulatory surgical centers, clinics, home healthcare, and hospitals each impose different handling, storage, and administration workflows, which in turn affect training requirements, packaging design, and support services. Taken together, these segmentation dimensions guide prioritization across R&D, regulatory strategy, manufacturing investment, and go-to-market planning, emphasizing the need for multidisciplinary alignment to achieve successful product adoption.

Regional differentiation in regulatory, clinical, and manufacturing environments is reshaping market entry strategies and investment priorities across global healthcare markets

Regional dynamics materially influence development priorities, reimbursement frameworks, and adoption trajectories for sustained release injectables, and a regionally differentiated approach is essential for effective strategy. In the Americas, regulatory pathways and payer systems create a landscape where clinical evidence and health-economic rationale are central to market access, and manufacturers commonly prioritize patient-centric devices and outcome studies that align with value-based care initiatives. The Americas also host notable contract development and manufacturing capacity, making it a focal point for scale-up and commercialization activities.

In Europe, Middle East & Africa, regulatory diversity and fragmented reimbursement structures require adaptive market entry tactics that leverage regional centers of excellence and local partnerships. This region often emphasizes harmonized safety and post-market surveillance, and the presence of sophisticated healthcare systems in parts of Europe supports early adoption of innovative sustained release formats when supported by real-world evidence and clinician education initiatives. Emerging markets within the region present opportunities for targeted access programs and alternative pricing models.

Asia-Pacific exhibits a mix of strong manufacturing ecosystems, active biopharmaceutical innovation, and rapidly evolving regulatory frameworks. Several economies in the region are investing in advanced materials and device manufacturing, offering strategic options for alternative sourcing and cost-effective production. Clinical development pathways here may offer expedited timelines in certain jurisdictions, and the region's large patient populations make it an important arena for outcome generation and scale, provided local regulatory and reimbursement hurdles are carefully navigated. Across all regions, regional policy shifts, trade dynamics, and healthcare delivery models will continue to shape where and how companies prioritize development and commercialization investments.

Strategic partnerships, platform business models, and differentiated manufacturing capabilities are defining competitive advantage in the sustained release injectables sector

Competitive dynamics among manufacturers, technology vendors, and service providers are evolving toward deeper collaboration and specialization to address the technical complexity of sustained release injectables. Established pharmaceutical organizations are increasingly partnering with material science specialists and device developers to expedite combination product development, while contract development and manufacturing organizations differentiate through integrated services that combine formulation expertise, aseptic filling, and device assembly. This interplay has heightened the importance of intellectual property around polymer formulations and device interfaces, with strategic licensing and cross-licensing becoming common routes to access enabling technologies.

Business models are also adapting; some developers focus on platform technologies that can be applied across therapeutic areas, capturing recurring revenue opportunities through licensing and toll manufacturing, whereas others pursue vertically integrated strategies to control critical inputs and retain margin. Strategic alliances with specialty chemical suppliers and device innovators are central to securing access to next-generation polymers and proprietary delivery mechanisms. Additionally, firms that invest in clinical and health-economic evidence generation strengthen their commercial positioning by demonstrating measurable adherence gains and patient-centric benefits, which aids negotiations with payers and provider networks.

The competitive landscape rewards organizations that combine scientific rigor with operational excellence, regulatory foresight, and clear value communication. Companies that optimize manufacturing scalability, shorten development timelines through modular validation approaches, and establish resilient supply chains will be better positioned to capture opportunity windows as adoption accelerates.

Practical, high-impact recommendations to de-risk development, strengthen supply chains, and accelerate commercial adoption of sustained release injectable solutions

Industry leaders should prioritize a set of practical, high-impact actions to convert technical progress into sustainable commercial outcomes. First, diversify polymer and component sourcing to reduce exposure to trade disruptions and support continuous supply; qualify alternate suppliers proactively and implement dual-sourcing strategies where feasible. Second, invest in material characterization and device compatibility testing early in development to de-risk later-stage integration challenges and accelerate regulatory submissions. Third, design clinical programs that incorporate patient-centric endpoints and real-world evidence collection to address payer demands for demonstrable adherence and outcomes improvements.

Fourth, strengthen relationships with contract development and manufacturing partners by establishing long-term collaboration frameworks that include co-investment in scale-up capabilities and technology transfer. Fifth, deploy flexible manufacturing approaches-such as modular cleanroom architectures and process intensification-to improve responsiveness to demand shifts and to enable cost-efficient scale. Sixth, pursue targeted regional strategies that align regulatory engagement, clinical trial design, and reimbursement planning with local health system priorities to maximize early adoption potential.

Finally, embed sustainability and lifecycle considerations into product development, recognizing that environmental stewardship and end-of-life device management are rising expectations from healthcare providers and payers. By implementing these recommendations, organizations can reduce technical and commercial risk while positioning their portfolios to capture durable value from sustained release injectable technologies.

A multi-method research approach combining regulatory review, expert interviews, patent and literature analysis, and supplier mapping to ensure validated strategic recommendations

The analysis underpinning this executive summary combined a multi-method research approach to ensure robustness and practical relevance. The methodology integrated a comprehensive review of primary regulatory documentation and clinical trial registries, targeted interviews with subject-matter experts spanning formulation scientists, device engineers, regulatory affairs professionals, and commercial leaders, and a systematic assessment of patent filings and scientific literature to map innovation trajectories. Supply chain mapping and supplier capability assessments were conducted using validated trade and procurement datasets, complemented by expert validation.

Findings were triangulated across data sources to reconcile technical trends with commercial and policy drivers, and draft conclusions were iteratively validated with independent industry practitioners to reduce bias. The approach emphasized qualitative insight and technical synthesis rather than numeric market projections, enabling granular recommendations tied to operational levers. Limitations include the rapid pace of technological change and policy shifts, which may alter specific supplier dynamics or regulatory interpretations; stakeholders are encouraged to use the report's frameworks for continuous monitoring and to commission targeted follow-ups where necessary.

Concluding synthesis that underscores the urgency for integrated scientific, operational, and commercial strategies to realize the potential of long-acting injectable therapies

Sustained release injectables represent a strategic intersection of material science, device engineering, and clinical strategy that is reshaping therapeutic delivery across multiple disease areas. The industry is at an inflection point in which successful commercialization requires not only compelling pharmacology but also integrated solutions that address manufacturing complexity, regulatory expectations, payer value propositions, and patient adoption pathways. Organizations that align cross-disciplinary capabilities, secure resilient supply chains, and generate robust real-world evidence will have a clear competitive advantage.

As technological options expand-from advanced biodegradable polymers to miniaturized delivery devices-companies must adopt pragmatic development roadmaps that prioritize de-risking and evidence generation. Trade policy and regional dynamics add layers of operational complexity, making flexible sourcing, regional manufacturing options, and strategic partnerships essential. The recommendations provided in this summary aim to guide executives in translating scientific advances into clinically meaningful and commercially successful products that meet the evolving needs of healthcare systems and patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sustained Release Injectables Market, by Product Type

  • 8.1. Cartridges
  • 8.2. Implantable Pumps
  • 8.3. Pre-Filled Syringes
  • 8.4. Unfilled Vials

9. Sustained Release Injectables Market, by Polymer Type

  • 9.1. Biodegradable Polymers
    • 9.1.1. PCL
    • 9.1.2. PLA
    • 9.1.3. PLGA
  • 9.2. Non-Biodegradable Polymers
    • 9.2.1. Polyethylene
    • 9.2.2. Polysiloxanes

10. Sustained Release Injectables Market, by Route Of Administration

  • 10.1. Epidural
  • 10.2. Intramuscular
  • 10.3. Intravitreal
  • 10.4. Subcutaneous

11. Sustained Release Injectables Market, by Application

  • 11.1. Hormonal Therapies
  • 11.2. Oncology
    • 11.2.1. Hematological Malignancies
    • 11.2.2. Solid Tumors
      • 11.2.2.1. Breast Cancer
      • 11.2.2.2. Lung Cancer
  • 11.3. Pain Management
  • 11.4. Vaccines

12. Sustained Release Injectables Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospitals

13. Sustained Release Injectables Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Sustained Release Injectables Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Sustained Release Injectables Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Sustained Release Injectables Market

17. China Sustained Release Injectables Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alkermes plc
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. DSM-Firmenich Group
  • 18.9. DURECT Corporation
  • 18.10. Eli Lilly and Company
  • 18.11. GlaxoSmithKline plc
  • 18.12. Halozyme Therapeutics, Inc.
  • 18.13. Hoffmann-La Roche Ltd
  • 18.14. Indivior PLC
  • 18.15. Johnson & Johnson
  • 18.16. MedinCell SA
  • 18.17. Novartis AG
  • 18.18. Oakwood Laboratories, LLC
  • 18.19. Otsuka Pharmaceutical Co., Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Pharmathen S.A.
  • 18.22. Sanofi S.A.
  • 18.23. Teva Pharmaceutical Industries Ltd.
  • 18.24. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CARTRIDGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CARTRIDGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY UNFILLED VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY UNFILLED VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY UNFILLED VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PCL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PCL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PCL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLGA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLGA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLGA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYSILOXANES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYSILOXANES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYSILOXANES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY EPIDURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY EPIDURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY EPIDURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)